Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Elongin BC Complex

  • Ronald C. Conaway
  • Joan W. Conaway
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1853-2


The mammalian elongin BC complex is a heterodimer, composed of the 118 amino acid ubiquitin-like elongin B protein and the 112 amino acid elongin C protein. The elongin BC complex interacts through a short, degenerate BC-box motif with multiple proteins, including the transcription factor elongin A, the von Hippel–Lindau (VHL) tumor suppressor protein, and members of the SOCS-box protein family.


The elongin B and C proteins were initially identified as positive regulatory subunits of the three-subunit elongin complex, which is one of several transcription factors capable of controlling the activity of the RNA polymerase II elongation complex. The three-subunit elongin complex was originally purified from rat liver nuclei by its ability to activate the overall rate of elongation by RNA polymerase II, by suppressing transient polymerase pausing at many sites within transcribed sequences. The elongin complex is composed of a transcriptionally active A subunit of...


Clear Cell Renal Carcinoma Prolyl Hydroxylase Spry Domain Retinal Angioma Substrate Recognition Subunit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Alexander WS, Hilton DJ (2004) The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22:503–529CrossRefPubMedGoogle Scholar
  2. Kamura T, Sato S, Haque D et al (1998) The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 12:3872–3881CrossRefPubMedPubMedCentralGoogle Scholar
  3. Kamura T, Koepp DM, Conrad MN et al (1999) Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657–661CrossRefPubMedGoogle Scholar
  4. Ohh M (2006) Ubiquitin pathway in VHL Cancer Syndrome. Neoplasia 8:623–629CrossRefPubMedPubMedCentralGoogle Scholar
  5. Stebbins CE, Kaelin WG, Pavletich NP (1999) Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284:455–461CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Stowers Institute for Medical ResearchKansasUSA